Cargando…
ASC nanobodies to counteract the consequences of inflammasome activation
Inflammasomes are multiprotein complexes that signal by oligomerizing the apoptosis speck‐like protein with caspase recruitment and activator domain (ASC) and are involved in multiple inflammatory, metabolic and degenerative diseases. Pharmacological targeting of specific inflammasomes with small mo...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174878/ https://www.ncbi.nlm.nih.gov/pubmed/35574976 http://dx.doi.org/10.15252/emmm.202216087 |
_version_ | 1784722335270436864 |
---|---|
author | Adriouch, Sahil Pelegrin, Pablo |
author_facet | Adriouch, Sahil Pelegrin, Pablo |
author_sort | Adriouch, Sahil |
collection | PubMed |
description | Inflammasomes are multiprotein complexes that signal by oligomerizing the apoptosis speck‐like protein with caspase recruitment and activator domain (ASC) and are involved in multiple inflammatory, metabolic and degenerative diseases. Pharmacological targeting of specific inflammasomes with small molecules is leading to the development of novel drugs for most common diseases. The targeting of ASC oligomers will result in a pan‐inflammasome treatment. In their study, Bertheloot et al (2022) developed specific anti‐ASC nanobodies and showed their efficacy to disaggregate already formed ASC oligomers and to treat inflammatory diseases in animal models. This approach represents a novel biologic‐based treatment for inflammasomes‐initiated inflammatory diseases. |
format | Online Article Text |
id | pubmed-9174878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91748782022-06-13 ASC nanobodies to counteract the consequences of inflammasome activation Adriouch, Sahil Pelegrin, Pablo EMBO Mol Med News & Views Inflammasomes are multiprotein complexes that signal by oligomerizing the apoptosis speck‐like protein with caspase recruitment and activator domain (ASC) and are involved in multiple inflammatory, metabolic and degenerative diseases. Pharmacological targeting of specific inflammasomes with small molecules is leading to the development of novel drugs for most common diseases. The targeting of ASC oligomers will result in a pan‐inflammasome treatment. In their study, Bertheloot et al (2022) developed specific anti‐ASC nanobodies and showed their efficacy to disaggregate already formed ASC oligomers and to treat inflammatory diseases in animal models. This approach represents a novel biologic‐based treatment for inflammasomes‐initiated inflammatory diseases. John Wiley and Sons Inc. 2022-05-16 /pmc/articles/PMC9174878/ /pubmed/35574976 http://dx.doi.org/10.15252/emmm.202216087 Text en © 2022 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | News & Views Adriouch, Sahil Pelegrin, Pablo ASC nanobodies to counteract the consequences of inflammasome activation |
title | ASC nanobodies to counteract the consequences of inflammasome activation |
title_full | ASC nanobodies to counteract the consequences of inflammasome activation |
title_fullStr | ASC nanobodies to counteract the consequences of inflammasome activation |
title_full_unstemmed | ASC nanobodies to counteract the consequences of inflammasome activation |
title_short | ASC nanobodies to counteract the consequences of inflammasome activation |
title_sort | asc nanobodies to counteract the consequences of inflammasome activation |
topic | News & Views |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174878/ https://www.ncbi.nlm.nih.gov/pubmed/35574976 http://dx.doi.org/10.15252/emmm.202216087 |
work_keys_str_mv | AT adriouchsahil ascnanobodiestocounteracttheconsequencesofinflammasomeactivation AT pelegrinpablo ascnanobodiestocounteracttheconsequencesofinflammasomeactivation |